Core Viewpoint - The company, Aimeike (300896.SZ), primarily sells its products to private medical beauty institutions, with a small proportion of sales occurring in public hospitals. The company plans to consider national policies and market demand to continue providing compliant products and services to public hospitals, addressing the growing demand for a better quality of life among the public [1] Group 1 - The company's products are mainly sold to private medical beauty institutions [1] - The sales amount in public hospitals is relatively small [1] - The company will adapt to national policies and market demand [1] Group 2 - The company aims to continuously provide compliant products and services to public hospitals [1] - The focus is on meeting the increasing demand for a better quality of life among the public [1]

Core Viewpoint - The medical beauty sector experienced a slight increase of 0.31% on February 4, with Jinbo Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4102.2, up by 0.85% [1] - The Shenzhen Component Index closed at 14156.27, up by 0.21% [1] - Jinbo Biological's stock price rose to 222.64, reflecting a gain of 3.55% [1] Group 2: Individual Stock Performance - Jinbo Biological led the medical beauty sector with a trading volume of 9236.31 hands and a transaction value of 2.02 billion yuan [1] - Aimei Ke's stock price increased by 0.51% to 148.32, with a trading volume of 42,100 hands and a transaction value of 6.20 billion yuan [1] - Huaxi Biological's stock price slightly decreased by 0.02% to 48.80, with a trading volume of 58,100 hands and a transaction value of 282 million yuan [1] Group 3: Capital Flow - The medical beauty sector saw a net outflow of 1.2797 million yuan from main funds, while retail investors experienced a net outflow of 2.70494 million yuan [1] - Jinbo Biological had a net inflow of 33.9145 million yuan from main funds, accounting for 16.83% of its trading volume [2] - Aimei Ke experienced a net outflow of 127.67 million yuan from main funds, with a net inflow of 22.7409 million yuan from retail investors [2]

Group 1 - The medical beauty sector increased by 3.9% on February 3, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 147.57, up 4.56%, and Huaxi Biological at 48.81, up 3.45% [1] Group 2 - The medical beauty sector saw a net inflow of 72.0481 million yuan from main funds, while retail funds experienced a net outflow of 41.6043 million yuan [1] - Ai Meike had a net inflow of 85.9952 million yuan from main funds, but retail funds saw a net outflow of 38.6841 million yuan [2] - Huaxi Biological experienced a net outflow of 10.4367 million yuan from main funds, with a net inflow of 14.2989 million yuan from speculative funds [2]

Core Viewpoint - The recent decision by Xiaohongshu to prohibit content collaboration with influencers in the medical beauty sector marks a significant shift in marketing strategies for medical beauty institutions, leading to increased pressure on their marketing efforts [1][2]. Group 1: Impact on Medical Beauty Marketing - Xiaohongshu's new regulations will render popular marketing tactics, such as "before and after comparisons" and "personal experience sharing," ineffective on the platform [1]. - The platform has been a crucial marketing channel for medical beauty institutions due to its high-quality user traffic, with some institutions spending over 1 million yuan annually on advertising [1]. - The tightening of regulations is expected to escalate marketing pressures for medical beauty institutions as they navigate a more competitive landscape [1]. Group 2: Historical Context and Regulatory Challenges - This is not the first time Xiaohongshu has targeted medical beauty content; in 2022, the platform conducted three rounds of strict governance, resulting in the banning of multiple medical beauty institutions and the cancellation of certifications for over a hundred private institutions [2]. - Xiaohongshu's core strength lies in "community trust," and the proliferation of false marketing could undermine this value, especially in a sector where decision-making is complex and costly [2]. - The platform faces a challenging balance between commercial monetization, maintaining community integrity, and adhering to regulatory compliance, leading to fluctuating policies in recent years [2].

Core Viewpoint - The medical beauty sector experienced a rise of 2.68% on February 2, with Huaxi Biological leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 2.48% and 2.69% respectively [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4015.75, down 2.48% [1] - The Shenzhen Component Index closed at 13824.35, down 2.69% [1] - The medical beauty sector stocks showed varied performance, with Huaxi Biological rising by 5.24% to a closing price of 47.18 [1] Group 2: Stock Details - Huaxi Biological (688363) had a trading volume of 118,200 shares and a transaction value of 562 million yuan [1] - Aimei Ke (300896) closed at 141.14, up 1.01%, with a trading volume of 47,500 shares and a transaction value of 683 million yuan [1] - ST Meigu (000615) closed at 3.08, up 0.33%, with a trading volume of 115,100 shares [1] - Jinbo Biological (920982) closed at 214.89, down 2.94%, with a trading volume of 9,949 shares and a transaction value of 217 million yuan [1] Group 3: Fund Flow Analysis - The medical beauty sector saw a net inflow of 100 million yuan from main funds, while retail investors experienced a net outflow of 59.89 million yuan [1] - Aimei Ke had a main fund net inflow of 55.54 million yuan, but a net outflow of 33.36 million yuan from retail investors [2] - Huaxi Biological experienced a main fund net inflow of 44.73 million yuan, with retail investors showing a net outflow of 27.92 million yuan [2]

Core Insights - The A-share market experienced fluctuations with the Shanghai Composite Index falling by 0.96% to 4117.95 points, while the Shenzhen Component Index decreased by 0.66%. The ChiNext Index, however, rose by 1.27% [1][7] - The total trading volume in the A-share market was 2.86 trillion RMB, with nearly 2900 stocks declining. The communication sector led the gains, while the non-ferrous metals sector saw the largest losses [1][7] - In the Hong Kong market, the Hang Seng Index dropped by 2.08%, and the Hang Seng Tech Index fell by 2.1%. In the overseas markets, all three major U.S. stock indices declined, with the Dow Jones down by 0.36%, the S&P 500 down by 0.43%, and the Nasdaq down by 0.94% [1][7] Important News - The Central Committee of the Communist Party of China emphasized the acceleration of the new round of technological revolution and industrial transformation, highlighting the importance of leveraging comparative advantages to promote breakthroughs in future industries [2][8] - The National Bureau of Statistics reported that the manufacturing PMI for January was 49.3%, a decrease of 0.8 percentage points month-on-month. The non-manufacturing PMI also fell to 49.4%, indicating a decline in business activity due to seasonal factors and insufficient market demand [2][8] Sector Analysis - In the social services sector, the proportion of heavy positions in funds increased, with 286 funds holding shares, up by 109 from the previous quarter. The total market value of holdings reached 5.57 billion RMB, an increase of 0.975 billion RMB [9][10] - The heavy position ratio for the social services sector was 0.06%, up by 0.01 percentage points, ranking 27th among 31 sectors, indicating potential for rebound as it remains below the 5-year average of 0.34% [9][10] - The hospitality and restaurant sectors showed slight recovery, while the education sector saw a significant decline in heavy position ratios [9][10] Individual Stocks - Leading stocks in the social services sector saw increased holdings, with the top ten stocks' combined heavy position ratio rising to 0.058%, an increase of 0.013 percentage points from the previous quarter. Notable stocks include Huace Testing, Shoulv Hotel, and JiuHua Tourism [10][11] - The report suggests focusing on companies benefiting from the upcoming long holiday and those positioned to take advantage of the Hainan Free Trade Port's opportunities [11] Beauty and Personal Care Sector - The beauty and personal care sector saw a decrease in fund allocation, with the total market value of A-shares at 255.096 billion RMB, down by 10.43% from the previous quarter. The fund allocation ratio was 0.14%, a decrease of 0.06 percentage points [12][13] - The personal care and cosmetics segments remain in a low allocation zone, while the medical beauty segment is in an over-allocated position [12][13] - Key stocks in the beauty and personal care sector include Jinbo Biological, Aimeike, and Baiya Shares, with their heavy position ratios declining compared to the previous quarter [14]

Investment Rating - The investment rating for the beauty and personal care industry is "outperforming the market" [4][22]. Core Insights - The fund allocation ratio for the beauty and personal care industry decreased to 0.14% in Q4 2025, down 0.06 percentage points from Q3 2025, indicating a continued low allocation status [1][3][9]. - The total market capitalization of the beauty and personal care industry reached 255.096 billion yuan in Q4 2025, reflecting a 10.43% decrease from Q3 2025 [1][9]. - The medical beauty sector remains in an over-allocated position, while personal care and cosmetics are in a low allocation zone [2][11]. Summary by Sections Industry Overview - In Q4 2025, the fund allocation ratio for personal care products was 0.03%, down 0.01 percentage points from Q3 2025, with an over-allocation ratio of -0.04% [2][13]. - The cosmetics sector saw a fund allocation ratio of 0.02% in Q4 2025, down 0.02 percentage points from Q3 2025, with an over-allocation ratio of -0.1% [2][13]. - The medical beauty sector's fund allocation ratio was 0.09% in Q4 2025, down 0.03 percentage points from Q3 2025, with an over-allocation ratio of 0.02% [2][13]. Individual Stocks - The top three stocks in the beauty and personal care sector by fund allocation in Q4 2025 were Jinbo Biological, Aimeike, and Baiya Shares, with a total heavy holding ratio of 0.05%, down 0.02 percentage points from Q3 2025 [2][15][19]. - Jinbo Biological had a heavy holding ratio of 0.0163%, Aimeike at 0.0156%, and Baiya Shares at 0.0040% in Q4 2025, all showing a decline compared to Q3 2025 [15][19]. Investment Recommendations - In the context of stabilizing the economy and expanding domestic demand, it is recommended to focus on: 1. Cosmetics and medical beauty: There is significant demand potential in the medium to long term, supported by regulatory policies favoring compliant companies [3][20]. 2. Personal care products: The growing emphasis on health and wellness among consumers suggests opportunities for leading companies with strong R&D capabilities [3][20].

证券之星消息，1月30日医疗美容板块较上一交易日下跌3.14%，爱美客领跌。当日上证指数报收于 4117.95，下跌0.96%。深证成指报收于14205.89，下跌0.66%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.07 | -1.92% | 12.54万 | 3883.90万 | | 920982 | 锦波生物 | 221.39 | -2.42% | 7085.98 | 1.58亿 | | 688363 | 华熙生物 | 44.83 | -3.20% | 4.64万 | 2.10亿 | | 300896 | 爱美客 | 139.73 | -3.22% | 3.76万 | 5.31亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出7658.45万元，游资资金净流入4438.38万元，散户 资金净流入3220.06万元。医疗美容板块个股资金流向见下表： | 代码 | | | | 名称 ｜主力净流入（元）｜主力净占比｜ ...

Core Viewpoint - *ST Meigu's 2025 performance forecast indicates expected revenue of approximately 850 to 1,050 million yuan, with a net loss attributable to shareholders projected between 550 to 390 million yuan. The company anticipates a significant increase in net assets by the end of the period due to the completion of its restructuring plan [1][1]. Group 1 - The company received a civil ruling from the Intermediate People's Court of Xiangyang on December 29, 2025, confirming the completion of its restructuring plan, which has effectively resolved its debt crisis and significantly improved its asset-liability structure [1][1]. - The restructuring involved introducing investors and adjusting equity, leading to a substantial increase in the company's net assets by the end of the reporting period [1][1]. Group 2 - The medical beauty business faces increasing competition and challenges in customer acquisition, resulting in a year-on-year decrease in revenue and profit, prompting the company to make impairment provisions for related assets [1][1]. - The biobased fiber business has not shown effective improvement, leading the company to also make impairment provisions for relevant production lines [1][1].

Company Overview - The company primarily operates in the bio-based fiber and medical beauty sectors [6] - It expects to achieve operating revenue of approximately 850 to 1,050 million yuan in 2025, with a net loss attributable to shareholders ranging from 550 to 390 million yuan [6] Financial Performance - The company has undergone a restructuring process, which has significantly improved its debt situation and asset-liability structure, leading to a substantial increase in net assets by the end of the reporting period [6] - The medical beauty business has faced intensified competition, resulting in a decrease in both revenue and profit, prompting the company to make impairment provisions for related assets [6] - The bio-based fiber business has not shown effective improvement, leading to additional impairment provisions for relevant production lines [6] Revenue and Profit Trends - Historical total revenue and net profit figures indicate fluctuations, with total revenue projected to decline in 2022 and 2023, followed by a recovery in 2024 and 2025 [7] - The year-on-year growth rates for total revenue and net profit have shown significant variability, with a notable decline of 36.92% in 2022 and a projected recovery of 19.77% in 2024 [7]